VYGR

Voyager Therapeutics, Inc.

NasdaqGSUSDEQUITY DELAYED

3.39

▲ 0.07 (2.02%)

MARKET · —

Price

Open

3.31

Prev close

3.32

Day high

3.44

Day low

3.30

Volume

415.85K

Market cap

—

P/E (TTM)

—

52W range

2.94 – 5.55

Trailing performance

Price return · vs SPY

Returnvs SPY

+3.67% +5.0%

+9.71% +6.0%

-7.88% -11.0%

-2.87% -13.9%

YTD

-13.74% -26.0%

+1.19% -18.8%

-63.70% -137.9%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

3.27

+3.55% from price

SMA 20

3.18

+6.55% from price

SMA 50

3.35

+1.30% from price

SMA 100

3.60

-5.79% from price

SMA 200

3.81

-11.05% from price

EMA 12

3.27

+3.51% from price

EMA 26

3.26

+3.98% from price

EMA 50

3.34

+1.31% from price

RSI (14)

57.1

Neutral

MACD (12,26,9)

0.01

Hist 0.04

ATR (14)

0.14

4.26% of price

Realised vol 30D

43.7%

Annualised

Bollinger upper

3.42

20, 2σ

Bollinger lower

2.94

20, 2σ

50 / 200 cross

Death

3.35 vs 3.81

Trend bias

Below 200

-11.05%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.33

More volatile than market

Correlation to SPY

0.28

Largely independent

Realised vol 30D

43.7%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-43.7%

Peak to trough

Max drawdown 5Y

-80.5%

Peak to trough

ATR 14

0.14

4.26% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.39

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

VYGR · links out to the publisher

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates Zacks · 16d ago Voyager Therapeutics: Q2 Earnings Snapshot Associated Press · 16d ago Voyager Reports Second Quarter 2026 Financial and Operating Results GlobeNewswire · 16d ago Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2 MT Newswires · 40d ago Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 GlobeNewswire · 40d ago Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s? Barrons.com · 40d ago Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money 24/7 Wall St. · 51d ago Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside Insider Monkey · 53d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.